Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins
Compass Pathways: Imminent Commercialization Should Provide Further Upside
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript
Compass Pathways shares rise on Q1 results, accelerated FDA review
Compass Pathways Q1 Earnings Call Highlights
Compass Pathways shares rise on Q1 results, accelerated FDA review
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Airbnb, Alphabet, Check Point Software, GlobalFoundries, Internatioinal Paper, Trade Desk, and More
These 3 Psychedelic Stocks Activated After Trump's Executive Order
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About
What Makes COMPASS Pathways PLC Sponsored ADR (CMPS) a Strong Momentum Stock: Buy Now?
How Much Upside is Left in COMPASS Pathways (CMPS)? Wall Street Analysts Think 136%
Compass Pathways: Red Hot Psychedelic Market For Pioneer With Near Term Psychedelic Filing In TRD
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments
This 4/20, Wall Street Is Betting on More Than Marijuana
How Trump's psychedelics executive order could unlock stalled cannabis reform
Why Compass Pathways Stock Rocketed 40% Today
Compass Pathways: The Bull Case Is Early, Not Wrong
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
Psychedelics stocks rise after Trump order expands research, access pathways
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training
Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways (NASDAQ:CMPS) & Elevance Health (NYSE:ELV) Financial Comparison
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
Compass Pathways Eyes Rolling FDA Filing for COMP360, Preps TRD Launch Ahead of Q3 Data
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
Compass Pathways Highlights Phase 3 COMP360 TRD Gains, 26-Week Durability and FDA Path at Conference
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise
Cathie Wood Pours $24 Million to This AI Software Stock
Compass Pathways Announces Pricing of $150 Million Public Offering
COMPASS Pathways plc (CMPS) Discusses Positive Phase III Results for COMP360 in Treatment-Resistant Depression Trials Transcript
Compass Pathways Launches Proposed $150.0 Million Public Offering
Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot
Why Did Compass Pathways Stock Rocket Higher Today?
Compass Pathways' depression treatment meets main goal in late‑stage study
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression